207 related articles for article (PubMed ID: 24289129)
1. Current standing and frontiers of gene therapy for meningiomas.
De La Garza-Ramos R; Flores-Rodríguez JV; Martínez-Gutiérrez JC; Ruiz-Valls A; Caro-Osorio E
Neurosurg Focus; 2013 Dec; 35(6):E4. PubMed ID: 24289129
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.
Ikeda K; Saeki Y; Gonzalez-Agosti C; Ramesh V; Chiocca EA
J Neurosurg; 1999 Jul; 91(1):85-92. PubMed ID: 10389885
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms.
Pham MH; Zada G; Mosich GM; Chen TC; Giannotta SL; Wang K; Mack WJ
Neurosurg Focus; 2011 May; 30(5):E7. PubMed ID: 21529178
[TBL] [Abstract][Full Text] [Related]
4. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
Choy W; Kim W; Nagasawa D; Stramotas S; Yew A; Gopen Q; Parsa AT; Yang I
Neurosurg Focus; 2011 May; 30(5):E6. PubMed ID: 21529177
[TBL] [Abstract][Full Text] [Related]
5. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for meningioma: improved gene delivery with targeted adenoviruses.
Dirven CM; Grill J; Lamfers ML; Van der Valk P; Leonhart AM; Van Beusechem VW; Haisma HJ; Pinedo HM; Curiel DT; Vandertop WP; Gerritsen WR
J Neurosurg; 2002 Aug; 97(2):441-9. PubMed ID: 12186474
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of meningiomas: from basic research to potential clinical applications.
Simon M; Boström JP; Hartmann C
Neurosurgery; 2007 May; 60(5):787-98; discussion 787-98. PubMed ID: 17460514
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas.
Evans JJ; Jeun SS; Lee JH; Harwalkar JA; Shoshan Y; Cowell JK; Golubic M
J Neurosurg; 2001 Jan; 94(1):111-7. PubMed ID: 11147878
[TBL] [Abstract][Full Text] [Related]
9. Meningiomas and neurofibromatosis for the oncologist.
Schrell UM; Fahlbusch R; Adams EF
Curr Opin Oncol; 1994 May; 6(3):247-53. PubMed ID: 8080853
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromatosis 2.
Baser ME; R Evans DG; Gutmann DH
Curr Opin Neurol; 2003 Feb; 16(1):27-33. PubMed ID: 12544854
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
[TBL] [Abstract][Full Text] [Related]
12. Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
Karsy M; Guan J; Cohen A; Colman H; Jensen RL
Neurosurg Clin N Am; 2016 Apr; 27(2):249-60. PubMed ID: 27012389
[TBL] [Abstract][Full Text] [Related]
13. Future treatment modalities for meningiomas: targeting of neurofibromatosis type 2 and Ras-regulated pathways.
Evans JJ; Lee JH; Park YS; Jeun SS; Harwalkar JA; Safayhi H; Golubic M
Neurosurg Clin N Am; 2000 Oct; 11(4):717-33. PubMed ID: 11082181
[No Abstract] [Full Text] [Related]
14. Current treatment options for meningioma.
Apra C; Peyre M; Kalamarides M
Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
[TBL] [Abstract][Full Text] [Related]
15. [Aberrant methylation of NF2, TIMP-3 and THBS1 genes and their diagnostic values in meningiomas].
Gong J; Zhu SG; Wu CY; Li XG; Liu YG; Ren XH; Zhang Y
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2889-92. PubMed ID: 23328233
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape of intracranial meningiomas.
Bi WL; Abedalthagafi M; Horowitz P; Agarwalla PK; Mei Y; Aizer AA; Brewster R; Dunn GP; Al-Mefty O; Alexander BM; Santagata S; Beroukhim R; Dunn IF
J Neurosurg; 2016 Sep; 125(3):525-35. PubMed ID: 26771848
[TBL] [Abstract][Full Text] [Related]
17. Intracranial meningiomas and neurofibromatosis type 2.
Aboukais R; Zairi F; Baroncini M; Bonne NX; Schapira S; Vincent C; Lejeune JP
Acta Neurochir (Wien); 2013 Jun; 155(6):997-1001; discussion 1001. PubMed ID: 23558725
[TBL] [Abstract][Full Text] [Related]
18. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG
J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391
[TBL] [Abstract][Full Text] [Related]
19. Related mechanisms, current treatments, and new perspectives in meningioma.
Inetas-Yengin G; Bayrak OF
Genes Chromosomes Cancer; 2024 May; 63(5):e23248. PubMed ID: 38801095
[TBL] [Abstract][Full Text] [Related]
20. Clinical course and management of intracranial meningiomas in neurofibromatosis type 2 patients.
Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(6):367-72. PubMed ID: 26652870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
